Total Funding
61
72
Total FundingPost-IPO Equity raised
Growth Score
-4 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
83924
BioPorto Diagnostics offers a wide range of diagnostic tests and antibodies to healthcare professionals in clinical and research settings.
- Carsten Buhl: Chief Executive OfficerPast Role: WS Audiology, President of AMERICAS
- Ole Larsen: CFO
About the Company
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Their pioneering product portfolio includes assays for underserved disease states, such as NGAL for acute kidney injury. They sell their products in more than 80
countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.
